- Home
- OPY vs MYGN Comparison
OPY vs MYGN Comparison
Compare OPY & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPY
- MYGN
- Stock Information
- Founded
- OPY 1881
- MYGN 1991
- Country
- OPY United States
- MYGN United States
- Employees
- OPY N/A
- MYGN N/A
- Industry
- OPY Investment Bankers/Brokers/Service
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- OPY Finance
- MYGN Health Care
- Exchange
- OPY Nasdaq
- MYGN Nasdaq
- Market Cap
- OPY 696.7M
- MYGN 744.7M
- IPO Year
- OPY N/A
- MYGN 1995
- Fundamental
- Price
- OPY $70.68
- MYGN $4.51
- Analyst Decision
- OPY
- MYGN Hold
- Analyst Count
- OPY 0
- MYGN 15
- Target Price
- OPY N/A
- MYGN $15.14
- AVG Volume (30 Days)
- OPY 78.1K
- MYGN 1.3M
- Earning Date
- OPY 07-25-2025
- MYGN 08-05-2025
- Dividend Yield
- OPY 1.01%
- MYGN N/A
- EPS Growth
- OPY 84.56
- MYGN N/A
- EPS
- OPY 6.74
- MYGN N/A
- Revenue
- OPY $1,358,354,000.00
- MYGN $831,300,000.00
- Revenue This Year
- OPY N/A
- MYGN N/A
- Revenue Next Year
- OPY N/A
- MYGN $6.68
- P/E Ratio
- OPY $10.46
- MYGN N/A
- Revenue Growth
- OPY 12.80
- MYGN 7.38
- 52 Week Low
- OPY $47.39
- MYGN $3.81
- 52 Week High
- OPY $73.12
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- OPY 69.63
- MYGN 40.01
- Support Level
- OPY $65.50
- MYGN $4.97
- Resistance Level
- OPY $71.05
- MYGN $5.37
- Average True Range (ATR)
- OPY 1.51
- MYGN 0.28
- MACD
- OPY 0.28
- MYGN -0.07
- Stochastic Oscillator
- OPY 88.03
- MYGN 2.34
About OPY Oppenheimer Holdings Inc. (DE)
Oppenheimer Holdings Inc conducts activities in the securities industry. The company is involved in retail securities brokerage, investment banking (both corporate and public finance), institutional sales and trading, market-making, research, trust services, and investment advisory and asset management services. The company has two segments: Wealth Management, and Capital Markets. IT generates maximum revenue from Wealth Management Segment which includes commissions and fee income earned on assets under management (AUM), net interest earnings on client margin loans and cash balances, fees from money market funds, custodian fees and other activities. The company generates the majority of its revenue from the Americas, with the rest from Europe, the Middle East, and Asia.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.